{
    "organizations": [],
    "uuid": "2b140146575fdcb698eb5533066e186a591395d4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sanofi-says-fda-to-review-zynquist/brief-sanofi-says-fda-to-review-zynquista-as-potential-treatment-for-type-1-diabetes-idUSFWN1ST0DL",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 22 (Reuters) - Sanofi SA:\n* FDA TO REVIEW ZYNQUISTAâ„¢ (SOTAGLIFLOZIN) AS POTENTIAL TREATMENT FOR TYPE 1 DIABETES\n* SANOFI - TARGET FDA ACTION DATE UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA) IS ANTICIPATED TO BE MARCH 22, 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-22T20:59:00.000+03:00",
    "crawled": "2018-05-23T15:23:05.045+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "sanofi",
        "sa",
        "fda",
        "review",
        "sotagliflozin",
        "potential",
        "treatment",
        "type",
        "diabetes",
        "sanofi",
        "target",
        "fda",
        "action",
        "date",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "anticipated",
        "march",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}